Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2
The experimentally established mechanism targets of Cytarabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | MTOR | P42345 | 2/20 | 0.97 |
| ▸ | THRB | P10828 | 1/20 | 0.97 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.97 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.97 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | GMNN | O75496 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.63 |
| ▸ | THPO | P40225 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | HBB | P68871 | 1/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | CDA | P32320 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytidine SCHEMBL27715166 | 1.00 | LMNA (0.97) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL339188 | 1.00 | LMNA (0.97) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL331331 | 1.00 | LMNA (0.97) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL9043997 | 1.00 | LMNA (0.97) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL339189 | 1.00 | LMNA (0.97) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL5961357 | 1.00 | LMNA (0.97) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL27878729 | 0.99 | LMNA (0.95) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL28325598 | 0.99 | LMNA (0.95) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL23066241 | 0.99 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL17993618 | 0.99 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2800 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4721734-A1 | USE OF PHARMACEUTICAL COMPOSITION COMPRISING MITOXANTRONE LIPOSOME AND CYTARABINE IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2026-04-08 | — | — | EP | claimed |
| WO-2026043843-A1 | TETRAHYDROPYRIMIDINE (THP) IONIZABLE LIPIDS FOR EFFICIENT MRNA DELIVERY | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, (US) | 2026-02-26 | — | — | WO | claimed |
| US-20260034101-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC INC (US) | 2026-02-05 | — | — | US | claimed |
| US-12383533-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2025-08-12 | — | — | US | claimed |
| CN-116003493-B | Method for recovering cupric ion and cytarabine | 常州金远药业制造有限公司 | 2025-02-28 | — | — | CN | claimed |
| CN-119451682-A | Use of pharmaceutical compositions comprising mitoxantrone liposomes and cytarabine for the treatment of acute myeloid leukemia | 石药集团中奇制药技术（石家庄）有限公司 | 2025-02-14 | — | — | CN | claimed |
| WO-2024245378-A1 | USE OF PHARMACEUTICAL COMPOSITION COMPRISING MITOXANTRONE LIPOSOME AND CYTARABINE IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA | 石药集团中奇制药技术（石家庄）有限公司 | 2024-12-05 | — | — | WO | claimed |
| US-20240398846-A1 | TREATMENTS FOR CACHEXIA | YINUOKE MEDICINE SCIENCE AND TECH CO LTD (CN) | 2024-12-05 | — | — | US | claimed |
| WO-2024215771-A1 | SUBSTITUTED PHENYL ETHYNYL PYRIMIDINES AS POTENT INHIBITORS OF ALPHAVIRUSES | SOUTHERN RESEARCH INSTITUTE (US) | 2024-10-17 | — | — | WO | claimed |
| CN-114028544-B | Pharmaceutical composition for mobilizing lymphoma and myeloma stem cells | 宁波大学附属人民医院 | 2024-09-10 | — | — | CN | claimed |
| WO-2001097749-A2 | THE USE OF SYNTHETIC, NON-HORMONAL 21-AMINOSTEROIDS AND THEREOF | KOTZE, GAVIN, SALOMON (ZA) | 2001-12-27 | — | — | WO | claimed |
| WO-2001097843-A2 | METHODS FOR ENHANCING ANTIBODY-INDUCED CELL LYSIS AND TREATING CANCER | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2001-12-27 | — | — | WO | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| WO-1997048725-A1 | NOVEL PEPTIDES FOR PREVENTION AND TREATMENT OF INFECTION | PEPTECH LIMITED (AU) | 1997-12-24 | — | — | WO | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| US-4145414-A | ANTIVIRAL, IMMUNOSUPPRESSIVE, ANTILEUKEMIA | THE UPJOHN COMPANY (US) | 1979-03-20 | — | — | US | claimed |